HELIOS-A: 18-month exploratory cardiac results from the phase 3 study of vutrisiran in patients with hereditary transthyretin-mediated amyloidosis

Garcia Pavia, P., Gillmore, J. D., Kale, P., Berk, J. L., Maurer, M. S., Conceição, I., Dicarli, M., Solomon, S., Chen, C., Arum, S., Vest, J., Grogan, M., & Hababou, C. (2023). HELIOS-A: 18-month exploratory cardiac results from the phase 3 study of vutrisiran in patients with hereditary transthyretin-mediated amyloidosis. Archives of Cardiovascular Diseases Supplements, 15(1), 31–32. https://doi.org/10.1016/j.acvdsp.2022.10.056
Authors:
Pablo García Pavía
Julian D. Gillmore
Parag Kale
John L. Berk
Mathew S. Maurer
Isabel Conceição
Marcelo F. DiCarli
Sonja R. Solomon
C. Chen
Seth Arum
John Vest
Martha Grogan
C. Hababou
Affiliated Authors:
Mathew S. Maurer
Publication Type:
Article
Unique ID:
10.1016/j.acvdsp.2022.10.056
Publication Date:
Data Source:
OpenAlex

Record Created: